-

Natera Recognized on U.S. News & World Report’s 2024 Best Companies to Work for in Healthcare Ranking

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that it has been named by U.S. News & World Report as one of the best companies to work for in healthcare.

Natera was ranked among 349 companies across 20 fields of work on factors contributing to job seekers’ decision-making when choosing a workplace that best meets their needs in their industries of interest. In healthcare specifically, Natera earned a spot on the industry list alongside companies across different elements of healthcare operations and services, including biotechnology, life sciences, pharmaceuticals, and hospital operations.

“At Natera, we are committed to fostering a positive workplace environment where employees can learn from one another, further develop in their careers, and continue to thrive – all while contributing to our very important mission,” said Steve Chapman, chief executive officer of Natera. “Natera is a great place to work because of our extremely talented employees, and we are proud to earn a spot on this list alongside so many esteemed companies across different dimensions of healthcare.”

This new recognition by U.S. News expands on the general 2023-2024 U.S. News Best Companies to Work For list by looking at how companies measure up to the expectations of their employees within their respective industries. The rankings take into account quality of pay, work-life balance, and opportunities for professional development and advancement by industry.

To calculate the U.S. News Best Companies to Work For by Industry lists, U.S. News only considered companies that were a part of the Russell 3000 index as of June 2023 and scored in the top 20% of their industry. Additionally, U.S. News required each company to have a minimum of 75 Glassdoor reviews written between 2020-2022 and grouped companies according to the Industry Classification Benchmark (ICB) used by the FTSE Russell.

To learn more about career opportunities at Natera and the core values that define company culture, please visit: www.natera.com/company/careers/.

About Natera

Natera™ is a global leader in cell-free DNA testing, dedicated to oncology, women’s health, and organ health. We aim to make personalized genetic testing and diagnostics part of the standard of care to protect health, and inform earlier, more targeted interventions that help lead to longer, healthier lives. Natera’s tests are validated by more than 150 peer-reviewed publications that demonstrate high accuracy. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in Austin, Texas and San Carlos, California. For more information, visit www.natera.com.

Contacts

Investor Relations: Mike Brophy, CFO, Natera, Inc., 510-826-2350, investor@natera.com
Media: Lesley Bogdanow, VP of Corporate Communications, Natera, Inc., pr@natera.com

Natera, Inc.

NASDAQ:NTRA

Release Versions

Contacts

Investor Relations: Mike Brophy, CFO, Natera, Inc., 510-826-2350, investor@natera.com
Media: Lesley Bogdanow, VP of Corporate Communications, Natera, Inc., pr@natera.com

More News From Natera, Inc.

Natera to Report its Third Quarter Results on November 5, 2026

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that it will release results for its third quarter ended September 30, 2026, after the market closes on November 5, 2026. Natera will host a conference call and webcast shortly thereafter at 4:30 p.m. ET. Earnings Conference Call Information   Event: Natera’s Third Quarter 2026 Financial Results Date: November 5, 2026 Time: 4:30 p.m. ET Live Dial-In: 1-833-461-57...

Signatera™ Genome with Phased and Structural Variants Highlighted in ESMO Presidential Symposium, Supporting the Critical Role of MRD-Guided Treatment in Bladder Cancer

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today provided a summary of key findings from the European Society for Medical Oncology (ESMO) Congress 2026. Following the presentation of several late-breaking datasets over the weekend, Natera’s technology was included in 25 abstracts, including 9 oral presentations, along with two concurrent publications. Results from the phase III VOLGA trial in muscle-invasive bladder canc...

Natera Shares Real-World Analyses and Data at ASN Kidney Week 2026, Highlighting the Critical Need for Genetic Testing with Renasight™

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced new data that was recently presented at the American Society of Nephrology (ASN) Kidney Week 2026, highlighting the unique value genetic testing can provide for patients with CKD. These 18 abstracts, including three oral presentations, add to the growing support for Renasight, Natera’s genetic test for CKD. Among the key findings were data from a large, real-worl...
Back to Newsroom